Switch theme
Sign up to access all valuation multiples
TYK Medicines Inc is a drug discovery research and development centre. The company and its subsidiaries are principally engaged in the research, development and commercialization of pharmaceutical products.
2017
147
LTM Revenue n/a
LTM EBITDA n/a
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TYK Medicines has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, TYK Medicines achieved revenue of n/a and an EBITDA of -$44.6M.
TYK Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TYK Medicines valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.7M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | $2.6M | XXX | XXX | XXX |
| Gross Margin | NaN% | Infinity% | XXX | XXX | XXX |
| EBITDA | -$37.6M | -$44.6M | XXX | XXX | XXX |
| EBITDA Margin | -660% | -Infinity% | XXX | XXX | XXX |
| Net Profit | n/a | -$40.0M | XXX | XXX | XXX |
| Net Margin | NaN% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 18, 2025, TYK Medicines's stock price is HKD 27 (or $4).
TYK Medicines has current market cap of HKD 10.1B (or $1.3B), and EV of HKD 9.9B (or $1.3B).
See TYK Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 18, 2025, TYK Medicines has market cap of $1.3B and EV of $1.3B.
TYK Medicines's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate TYK Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TYK Medicines and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -28.4x | XXX | XXX | XXX |
| P/E | -26.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -35.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTYK Medicines's NTM/LTM revenue growth is n/a
TYK Medicines's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.2M for the same period.
Over next 12 months, TYK Medicines's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TYK Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TYK Medicines and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TYK Medicines acquired XXX companies to date.
Last acquisition by TYK Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . TYK Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TYK Medicines founded? | TYK Medicines was founded in 2017. |
| Where is TYK Medicines headquartered? | TYK Medicines is headquartered in Hong Kong. |
| How many employees does TYK Medicines have? | As of today, TYK Medicines has 147 employees. |
| Is TYK Medicines publicy listed? | Yes, TYK Medicines is a public company listed on HKG. |
| What is the stock symbol of TYK Medicines? | TYK Medicines trades under 02410 ticker. |
| When did TYK Medicines go public? | TYK Medicines went public in 2024. |
| Who are competitors of TYK Medicines? | Similar companies to TYK Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TYK Medicines? | TYK Medicines's current market cap is $1.3B |
| Is TYK Medicines profitable? | Yes, TYK Medicines is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
